Opus Genetics (IRD) is having a good Wednesday. The clinical-stage biopharmaceutical company reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial for OPGx-BEST1, a gene therapy designed to tackle the underlying genetic cause of BEST1-related inherited retinal diseases. Shares jumped 46.66% to $6.36, hitting a new 52-week high.

Here's what happened: all five trial participants showed clinically meaningful improvements in visual function, and four of them also displayed key structural retinal recoveries. That's a solid signal for a therapy that aims to fix a genetic problem rather than just manage symptoms.

Positive Visual and Structural Outcomes

The low-dose cohort included patients with Best vitelliform macular dystrophy (BVMD) and autosomal recessive bestrophinopathy (ARB). The results were encouraging across the board:

• Best-corrected visual acuity improved in 60% of subjects.
• 75% of evaluable participants showed gains in retinal sensitivity, as measured by microperimetry.
• 67% of BVMD patients had a reduction of vitelliform material (the fatty buildup that characterizes the disease).
• All ARB patients experienced complete resolution of intraretinal fluid.

And importantly, the therapy maintained a favorable safety profile. No serious adverse events, no dose-limiting toxicities, and no intraocular inflammation. That's the kind of clean safety data that makes regulators and investors sit up and take notice.

Regulatory Alignment and Phase 3 Roadmap

Opus Genetics met with the U.S. Food and Drug Administration in August 2026 to finalize potential endpoints for a pivotal trial. The two sides aligned on a primary endpoint that measures microperimetry improvement alongside patient-reported outcomes for a randomized controlled trial. That's a meaningful step, because having regulatory buy-in on what you're measuring can save a lot of headaches down the road.

The company plans to complete manufacturing requirements in early 2027, with Phase 3 patient dosing expected to start later that year. So there's still work to do, but the path forward is getting clearer.

Cohort Expansion and Market Opportunity

Opus Genetics isn't resting on these results. The company has already moved on to a higher-dose second cohort, over-enrolling eight participants to further evaluate safety and efficacy. Topline three-month data from this group, along with six-month data for BVMD participants in the first cohort, are expected in the second quarter of 2027.

There's also a bigger picture here. New survey research from Triangle Insights Group suggests the global target population for BEST1-related diseases is about 45,400 symptomatic patients. That's significantly larger than prior estimates, which means the addressable market for OPGx-BEST1 could be bigger than investors initially thought.

For a company with a promising therapy and a clearer regulatory path, that's a compelling story. The stock's reaction on Wednesday reflects that optimism, but the real test will come with the Phase 3 data. For now, Opus Genetics is making the right moves, and the early signs are encouraging.